Header Logo

Connection

Weiyi Peng to Cell Line, Tumor

This is a "connection" page, showing publications Weiyi Peng has written about Cell Line, Tumor.
Connection Strength

0.579
  1. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. J Immunother Cancer. 2024 Sep 23; 12(9).
    View in: PubMed
    Score: 0.213
  2. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021 02; 9(2).
    View in: PubMed
    Score: 0.166
  3. Development of a RIPK1 degrader to enhance antitumor immunity. Nat Commun. 2024 Dec 16; 15(1):10683.
    View in: PubMed
    Score: 0.054
  4. UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024 Dec 17; 5(12):101834.
    View in: PubMed
    Score: 0.054
  5. IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
    View in: PubMed
    Score: 0.054
  6. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res. 2019 Nov 01; 25(21):6429-6442.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.